This Week in Medical Journals: June 2026 Highlights

This monthly roundup pulls together the developments worth a UK clinician's attention. For weekly digests tailored to your specialty — every article from the top five journals, summarised — start your free trial.

June 2026 is dominated by guidance changes rather than single trials. Four NICE developments are reshaping prescribing across primary care this quarter. Here is what changed and where to read the detail.

Women's health: a non-hormonal option for menopause

NICE recommended fezolinetant (Veoza) for moderate to severe vasomotor symptoms when HRT is unsuitable — technology appraisal TA1143, with around 500,000 people estimated eligible. HRT remains first-line. Separately, NICE updated the NG23 menopause guideline on 15 April with revised advice on unscheduled bleeding while on systemic HRT.

Full summary: Menopause and HRT guidance UK 2026.

Obesity and metabolic: tirzepatide enters the GP QOF

From 1 April 2026, tirzepatide (Mounjaro) prescribing for obesity entered the 2026/27 GP contract via new QOF indicators (NICE TA1026). Eligibility starts at BMI ≥35, with a lower threshold for several ethnic groups — but whether you can prescribe depends on local commissioning.

Full summary: Tirzepatide in the GP QOF 2026/27.

Diabetes: SGLT2 inhibitors first-line

The February 2026 NG28 update — still working through into practice — made SGLT2 inhibitors first-line for almost all adults with type 2 diabetes, with metformin reserved for those who cannot use them. The two metabolic changes together make this a heavy quarter for primary-care prescribing review.

Full summary: NICE NG28 February 2026: SGLT2 inhibitors first-line.

Exams and training: MRCP(UK) fees and Part 1 delivery

For trainees: MRCP(UK) fees rise 3.6% from 1 July 2026, and Part 1 moves to in-centre delivery from the September diet. If you are sitting this year, both affect planning.

Full summary: MRCP PACES 2026: fees, Part 1 changes, and a study plan.

The pattern this month

The through-line is prescribing change in primary care: two metabolic shifts (tirzepatide, SGLT2) and a new menopause option, all landing in the same quarter. If you see adults in general practice, the highest-yield reading this month is the QOF and NG28 detail — both change what you do on a Monday morning.

Every week, thousands of papers and a steady stream of guidance updates land. Staying current is foundational to good practice — and hard to do in a full clinical week. That is why The Monday Clinical Brief exists: to distil the signal from the noise and deliver it to your inbox every Monday, tailored to your specialty. For the bigger picture, see our pillar guide on how to keep up with the medical literature.

Start your free trial — £20 a year, no advertising.